Question Bank › Nobody is coming: management describes a market

Nobody is coming: management describes a market it must build itself, and the first buyers have started paying

Calls Tested
466
Answered YES
8
Hit Rate
1.7%
rare by design

Noah Holdings Limited (NOAH) — this company's answers

NO on the Q1 2024 call 2024-05-30 D
The model's full reasoning — Q1 2024 call → NO我们根据提供的财报电话会议记录来判断。管理层是否描述了公司正在创造一个新市场,而不是争夺现有市场份额?以及这种转化是否已经开始成功,有实际付费买家? 在电话会议中,管理层多次提到: - 国内高净值客户对投资变得谨慎,非合规财富管理公司倒闭,监管环境更严格。 - 海外业务扩张,但强调“管理讲中文的客户”对全球资产配置的需求。 - 他们正在扩大海外RM团队,目标是200人。 - 他们提到“教育”客户?实际上,他们提到“持续投资者教育”作为他们历史的一部分。 - 他们提到“建立信任”和“服务管理讲中文的高净值投资者”。 - 他们提到“我们的目标是增加美元AUA从80亿到200亿”。 - 他们提到“海外在线财富管理平台”和“代理客户”等。 但关键问题是:管理层是否明确表示,他们的增长受限于改变客户习惯和认知,而不是竞争?他们是否描述了客户需要被教育、转换、认证等?在记录中,管理层提到“高净值个人变得越来越谨慎”,但并没有明确说“我们必须教育客户”或“客户必须改变他们的习惯”。他们提到“投资者教育”作为他们历史的一部分,但并没有说当前的主要障碍是教育客户。 在回答关于收入下降的问题时,他们提到“国内业务收入下降是由于主动重组”和“海外业务增长但尚未完全反映在收入中”。他们提到“现金管理产品”和“定期存款”作为客户偏好,但并没有说客户需要被转换。 在回答关于保险佣金下降时,他们说“我们的RM更专注于为客户提供长期价值”,但并没有说客户需要被教育。 在回答关于投资情绪时,他们说“我们没有看到高净值投资者情绪的显著改善”,但并没有说他们正在做市场创造工作。 在回答关于收入展望时,他们说“我们的策略是确保国内合规和稳定,同时部署资源到海外”,但并没有说他们正在创造市场。 在回答关于费用率时,他们说“现金管理产品自然有较低的费用率”,但并没有说客户需要被转换。 在回答关于国内保险时,他们说“我们专注于满足退休、福祉和医疗需求的产品”,但并没有说客户需要被教育。 在回答关于海外业务时,他们说“我们正在扩大海外RM团队”,但并没有说他们正在教育客户。 在回答关于“管理讲中文的客户”时,他们说“我们致力于为管理讲中文的高净值投资者提供高质量资产配置服务”,但并没有说这些客户需要被教育。 在回答关于“代理客户”时,他们说“我们正在为EAM和家族办公室提供SaaS平台”,但并没有说这些客户需要被教育。 在回答关于“在线财富管理”时,他们说“在线财富管理正在成为我们的新渠道”,但并没有说客户需要被教育。 在回答关于“投资者教育”时,他们说“我们通过持续的投资者教育来增强对财富管理和投资的理解”,但这是历史性的,并不是当前的主要障碍。 在回答关于“市场创造”时,没有明确提到。 在回答关于“转化”时,他们提到“海外注册客户增长17.1%”,“购买现金管理产品的客户增长89.4%”,“海外活跃高净值客户增长39.6%”等,这些是实际数字,表明有付费客户。但这是否表明“转化”正在成功?他们确实有增长,但这是否是“从旧方式转换到公司方式”的转化?他们提到“海外业务增长”,但并没有说这些客户是从旧方式转换过来的。 管理层没有明确说“我们正在创造市场”或“客户必须改变他们的习惯”。他们更多是在说“我们正在扩展海外业务”和“我们正在增加RM团队”。他们提到“管理讲中文的客户”对全球资产配置的需求,但并没有说这些客户需要被教育。 在回答关于“国内业务”时,他们说“我们正在减少分支机构和优化成本”,但并没有说他们正在教育客户。 在回答关于“海外业务”时,他们说“我们正在增加海外RM团队”,但并没有说他们正在教育客户。 在回答关于“产品”时,他们说“我们正在推出高收益美元产品”,但并没有说客户需要被教育。 在回答关于“竞争”时,他们没有提到竞争对手,但也没有说主要障碍是惯性。 在回答关于“市场创造”时,没有明确。 因此,根据提供的记录,管理层没有明确描述公司正在做市场创造工作,即教育客户、改变习惯等。他们更多是在描述业务扩展和重组。虽然他们提到“投资者教育”作为历史,但并没有说当前的主要障碍是教育客户。 此外,他们提到“海外业务增长”和“客户数量增加”,但这是否是“转化”成功?他们确实有付费客户,但这是否是“从旧方式转换”的?他们提到“海外注册客户”和“购买现金管理产品的客户”,但并没有说这些客户是从国内业务转换过来的。 因此,我认为答案是否定的。 最终答案:NO

← Back to the full NOAH analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe the company as CREATING A MARKET THAT DOES NOT YET PROPERLY EXIST — that is, does management convey that the main obstacle in front of the business is not competition or price but the fact that the buyers themselves must first be TAUGHT, CONVERTED, QUALIFIED, OR HAVE THEIR OWN HABITS AND SYSTEMS CHANGED before they can buy at all — AND does management report that this conversion work has now begun to succeed with real paying buyers in the recent period? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation with both halves present as a present-tense reality: (1) THE COMPANY IS DOING MARKET-CREATION WORK, NOT MARKET-SHARE WORK. Management describes effort spent on getting the world ready to buy, rather than on beating rivals for demand that already exists. Any genuine expression of this counts, and the form varies widely across industries — for example: management explaining that customers must be educated on a category, method, material, or approach they do not yet understand or trust; that buyers have to change an entrenched practice, workflow, standard, specification, protocol, or supply arrangement in order to adopt; that the company is spending its time training, certifying, demonstrating, running side-by-side comparisons, or working through customers' internal validation, testing, trial, or approval processes; that adoption is slow because decision-makers have never bought anything like this and there is no existing budget line, reimbursement path, permitting route, or procurement category for it; that the company is having to build the surrounding conditions of its own market — installers, prescribers, applicators, inspectors, dealers, code acceptance, industry awareness, or downstream capability — before volume can flow; or that the company's chief competitor is inertia, the status quo, or "the way it has always been done" rather than another vendor. Management should convey that this conversion problem, rather than winning a competitive bid, is what actually governs how fast the business grows. (2) THE CONVERSION IS NOW ACTUALLY WORKING, WITH MONEY BEHIND IT. Management points to concrete evidence from the recent period that the resistance is giving way and buyers are crossing over: converts who have moved from the old way to the company's way and are now purchasing; customers who completed their evaluation, testing, or internal approval and have begun ordering; adoption spreading from the earliest believers to more conventional or larger buyers; practices, specifications, or standards beginning to be written the company's way; or the pace of conversions picking up relative to what the company used to achieve. The evidence must be present-tense and paid — real orders, customers, deployments, or usage happening now — not merely interest, education efforts underway, or a large market management believes exists. The essence is ONE phenomenon: a company whose growth is gated by how fast it can change other people's minds and habits, which has just started to win that argument at scale. The industry, the entrenched habit being displaced, and the form of the conversion may vary widely. Answer NO if the company competes for demand that plainly already exists — bidding, winning share, out-selling rivals, or serving an established buying pattern — however well it is doing. NO if management merely asserts a large addressable market, a superior product, or that customers "just need to see it," without describing an adoption barrier of habit, understanding, qualification, or established practice that must be overcome first. NO if the education, trialing, or qualification work is described with nothing yet converting into paying business — pilots without orders, interest without commitment, a market being "developed" with no crossings to point to. NO if the conversion described is chiefly the company's own customers upgrading to its newer product generation rather than outsiders changing their existing practice. NO if the barrier described is purely a pending external approval or a single regulatory gate with no buyer-behavior change involved. NO if management is chiefly explaining that adoption has stalled, slowed, or proven harder than expected with no recent progress. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CALX Calix, Inc. Q1 2023 2023-04-20 C+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
HLNE Hamilton Lane Incorporated Q1 2023 2022-08-02 C+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
ALKS Alkermes plc Q3 2018 2018-10-23 C
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C

How the model reasoned

ILMN · Q1 2018 → YESThe question is whether management describes the company as creating a market that doesn't yet properly exist, where the main obstacle is teaching/converting buyers, changing their habits, and that th...YES The transcript shows management framing Illumina's growth as market creation in the "earliest stages of the genomics journey," where the core obstacle is buyer education, habit change, and qualification rather than competing for existing demand. They describe heavy investment in studies (Harvard Pilgrim NIPT, MiSeq rugged, UK Biobank, 100k Genomes) to generate clinical/economic evidence for payers and physicians, regulatory progress (CMS NCD, FDA 23andMe BRCA approval), and expanding reimbursement paths. This is explicitly positioned as overcoming inertia and entrenched practices ("the way it has always been done") before volume flows.
EXFY · Q2 2022 → YESThe question is whether management describes the company as creating a market that doesn't yet properly exist, with both market-creation work and successful conversion with paying buyers. YES The transcript shows David Barrett describing the SMB expense-management market as "largely untouched" with "hundreds of millions of businesses" where "virtually none of them do anything," positioning Expensify as the first to introduce concepts like real-time expense scanning and pre-accounting through ExpensiCon to educate and change accounting-industry habits. This frames the core obstacle as buyer conversion and habit change rather than direct rivalry. He contrasts this with competitors retreating to enterprise sales due to defaults and cost pressures, while Expensify's bottom-up model and Free Plan enable early-stage onboarding.
SGRY · Q2 2022 → YESThe question is whether management describes the company as creating a market that doesn't yet properly exist, where the main obstacle is teaching/converting buyers, changing their habits, and that th...YES The transcript shows management framing the core growth driver as a site-of-care shift that requires buyers (physicians, payers, patients) to change entrenched habits and systems: physicians must be recruited and trained to perform procedures in ASCs rather than hospitals; payers must adopt value-based incentives and capitated models to move volume 5-figure discounts; patients must accept lower-cost, high-quality outpatient settings. This is presented as the primary obstacle to faster growth, not competitive bidding for already-existing demand.

More from the question bank

Insulated through the downturnThe bridge is already builtManagement volunteers specific, checkable nuScarcity of the company's own outputThe company is being paid to solve a problemBet-the-company financing already spent on hAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.